C Mee Ling Munier1, David van Bockel2, Michelle Bailey2, Susanna Ip2, Yin Xu2, Sheilajen Alcantara3, Sue Min Liu4, Gareth Denyer5, Warren Kaplan4, Kazuo Suzuki6, Nathan Croft7, Anthony Purcell7, David Tscharke8, David A Cooper6, Stephen J Kent9, John J Zaunders6, Anthony D Kelleher6. 1. The Kirby Institute for infection and immunity in society, UNSW Australia, Sydney, NSW, Australia. Electronic address: cmunier@kirby.unsw.edu.au. 2. The Kirby Institute for infection and immunity in society, UNSW Australia, Sydney, NSW, Australia. 3. Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia. 4. The Garvan Institute, Sydney, NSW, Australia. 5. School of Molecular Bioscience, Faculty of Science, The University of Sydney, NSW, Australia. 6. The Kirby Institute for infection and immunity in society, UNSW Australia, Sydney, NSW, Australia; St Vincent's Hospital, Sydney, NSW, Australia. 7. Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia. 8. John Curtin School of Medical Research, The Australian National University, Canberra, ACT, Australia. 9. Department of Microbiology and Immunology, Peter Doherty Institute, University of Melbourne, Melbourne, VIC, Australia; Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Health, Central Clinical School, Monash University Melbourne, VIC, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, VIC, Australia.
Abstract
BACKGROUND: Smallpox was eradicated by a global program of inoculation with Vaccinia virus (VV). Robust VV-specific CD4 T-cell responses during primary infection are likely essential to controlling VV replication. Although there is increasing interest in cytolytic CD4 T-cells across many viral infections, the importance of these cells during acute VV infection is unclear. METHODS: We undertook a detailed functional and genetic characterization of CD4 T-cells during acute VV-infection of humans. VV-specific T-cells were identified by up-regulation of activation markers directly ex vivo and through cytokine and co-stimulatory molecule expression. At day-13-post primary inoculation with VV, CD38highCD45RO+ CD4 T-cells were purified by cell sorting, RNA isolated and analysed by microarray. Differential expression of up-regulated genes in activated CD4 T-cells was confirmed at the mRNA and protein levels. We compared analyses of VV-specific CD4 T-cells to studies on 12 subjects with primary HIV infection (PHI). VV-specific T-cells lines were established from PBMCs collected post vaccination and checked for cytotoxicity potential. RESULTS: A median 11.9% CD4 T-cells were CD38highCD45RO+ at day-13 post-VV inoculation, compared to 3.0% prior and 10.4% during PHI. Activated CD4 T-cells had an up-regulation of genes related to cytolytic function, including granzymes K and A, perforin, granulysin, TIA-1, and Rab27a. No difference was seen between CD4 T-cell expression of perforin or TIA-1 to VV and PHI, however granzyme k was more dominant in the VV response. At 25:1 effector to target ratio, two VV-specific T-cell lines exhibited 62% and 30% cytotoxicity respectively and CD107a degranulation. CONCLUSIONS: We show for the first time that CD4 CTL are prominent in the early response to VV. Understanding the role of CD4 CTL in the generation of an effective anti-viral memory may help develop more effective vaccines for diseases such as HIV. Crown
BACKGROUND:Smallpox was eradicated by a global program of inoculation with Vaccinia virus (VV). Robust VV-specific CD4 T-cell responses during primary infection are likely essential to controlling VV replication. Although there is increasing interest in cytolytic CD4 T-cells across many viral infections, the importance of these cells during acute VV infection is unclear. METHODS: We undertook a detailed functional and genetic characterization of CD4 T-cells during acute VV-infection of humans. VV-specific T-cells were identified by up-regulation of activation markers directly ex vivo and through cytokine and co-stimulatory molecule expression. At day-13-post primary inoculation with VV, CD38highCD45RO+ CD4 T-cells were purified by cell sorting, RNA isolated and analysed by microarray. Differential expression of up-regulated genes in activated CD4 T-cells was confirmed at the mRNA and protein levels. We compared analyses of VV-specific CD4 T-cells to studies on 12 subjects with primary HIV infection (PHI). VV-specific T-cells lines were established from PBMCs collected post vaccination and checked for cytotoxicity potential. RESULTS: A median 11.9% CD4 T-cells were CD38highCD45RO+ at day-13 post-VV inoculation, compared to 3.0% prior and 10.4% during PHI. Activated CD4 T-cells had an up-regulation of genes related to cytolytic function, including granzymes K and A, perforin, granulysin, TIA-1, and Rab27a. No difference was seen between CD4 T-cell expression of perforin or TIA-1 to VV and PHI, however granzyme k was more dominant in the VV response. At 25:1 effector to target ratio, two VV-specific T-cell lines exhibited 62% and 30% cytotoxicity respectively and CD107a degranulation. CONCLUSIONS: We show for the first time that CD4 CTL are prominent in the early response to VV. Understanding the role of CD4 CTL in the generation of an effective anti-viral memory may help develop more effective vaccines for diseases such as HIV. Crown
Authors: Lauren E Higdon; Ayah A Ahmad; Steven Schaffert; Kenneth B Margulies; Jonathan S Maltzman Journal: Front Immunol Date: 2022-06-28 Impact factor: 8.786
Authors: Bonnie Chen; Stephen R Morris; Soumya Panigrahi; Gillian M Michaelson; Jonathan M Wyrick; Alexey A Komissarov; Daria Potashnikova; Anna Lebedeva; Souheil-Antoine Younes; Karem Harth; Vikram S Kashyap; Elena Vasilieva; Leonid Margolis; David A Zidar; Scott F Sieg; Carey L Shive; Nicholas T Funderburg; Sara Gianella; Michael M Lederman; Michael L Freeman Journal: J Immunol Date: 2020-03-30 Impact factor: 5.422
Authors: Jennifer A Juno; David van Bockel; Stephen J Kent; Anthony D Kelleher; John J Zaunders; C Mee Ling Munier Journal: Front Immunol Date: 2017-01-23 Impact factor: 7.561
Authors: Raquel Toribio-Fernández; Virginia Zorita; Vera Rocha-Perugini; Salvador Iborra; Gloria Martínez Del Hoyo; Raphael Chevre; Beatriz Dorado; David Sancho; Francisco Sanchez-Madrid; Vicente Andrés; Jose-Maria Gonzalez-Granado Journal: Cell Death Dis Date: 2018-01-08 Impact factor: 8.469
Authors: Z Li; M Khanna; S L Grimley; P Ellenberg; C A Gonelli; Wen Shi Lee; T H Amarasena; A D Kelleher; D F J Purcell; S J Kent; C Ranasinghe Journal: Sci Rep Date: 2020-12-16 Impact factor: 4.379
Authors: Amélie Cachot; Mariia Bilous; Yen-Cheng Liu; Xiaokang Li; Margaux Saillard; Mara Cenerenti; Georg Alexander Rockinger; Tania Wyss; Philippe Guillaume; Julien Schmidt; Raphaël Genolet; Giuseppe Ercolano; Maria Pia Protti; Walter Reith; Kalliopi Ioannidou; Laurence de Leval; Joseph A Trapani; George Coukos; Alexandre Harari; Daniel E Speiser; Alexander Mathis; David Gfeller; Hatice Altug; Pedro Romero; Camilla Jandus Journal: Sci Adv Date: 2021-02-26 Impact factor: 14.136
Authors: Cory J Knudson; Maria Férez; Pedro Alves-Peixoto; Dan A Erkes; Carolina R Melo-Silva; Lingjuan Tang; Christopher M Snyder; Luis J Sigal Journal: J Virol Date: 2021-07-14 Impact factor: 5.103
Authors: Katie Frith; C Mee Ling Munier; Lucy Hastings; David Mowat; Meredith Wilson; Nabila Seddiki; Rebecca Macintosh; Anthony D Kelleher; Paul Gray; John James Zaunders Journal: Int J Mol Sci Date: 2021-05-18 Impact factor: 5.923